
HanchorBio Partners With InxMed to Expand HCB101 Oncology Pipeline
A strategic memorandum of understanding between HanchorBio and InxMed marks a shift in development for HCB101, a lead SIRPα-Fc fusion protein. The companies intend to evaluate whether combining this immune-activating asset with InxMed’s specialized pipeline could overcome drug resistance and stromal barriers in difficult-to-treat solid tumors.






















